Drug intelligence / Profile preview

GSK3003898A

Development stage: Unknown
Lead developer: GSK
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**GSK3003898A** is an investigational GSK respiratory syncytial virus vaccine formulation containing 60 micrograms of nonadjuvanted RSV prefusion fusion glycoprotein F. It was evaluated as formulation 2 in randomized Phase 2 studies in healthy, nonpregnant women, where it was administered as a single intramuscular dose to induce neutralizing and palivizumab-competing antibody responses against RSV. This historical early RSV prefusion-F program is distinct from GSK's later licensed adjuvanted RSV vaccine, Arexvy.

Other names: RSV vaccine GSK3003898A

Targets

RSV F (Respiratory syncytial virus fusion protein)

Beyond the preview

Go deeper on GSK3003898A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK3003898A.

Explore the full profile